CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma
- PMID: 23365135
- DOI: 10.1158/0008-5472.CAN-12-3227
CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma
Abstract
Sustained activation of the stress-regulated transcription factor NRF2 (NFE2L2) is a prominent feature of many types of cancer, implying that mutations driving NRF2 may be important to tumor progression. In hereditary type 2 papillary renal cell carcinoma (PRCC2, also known as hereditary leiomyomatosis and renal cell cancer), NRF2 activation is a direct consequence of the accumulation of intracellular fumarate, a result of fumarate hydratase (FH) inactivation, but it is not clear how NRF2 may be activated in sporadic forms of PRCC2. Here we show that somatic mutations in NRF2, CUL3, and SIRT1 are responsible for driving the NRF2 activation phenotype in sporadic PRCC2. Transcriptome sequencing revealed the expression pattern of mutant alleles of NRF2, CUL3, and SIRT1 and also confirmed NRF2 activation in clinical specimens. Our results show a convergence in somatic mutations in sporadic PRCC2 with FH mutation in hereditary PRCC2.
©2013 AACR.
Similar articles
-
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.Cancer Cell. 2011 Oct 18;20(4):511-23. doi: 10.1016/j.ccr.2011.08.024. Cancer Cell. 2011. PMID: 22014576
-
Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.BMC Cancer. 2018 Jan 6;18(1):46. doi: 10.1186/s12885-017-3907-z. BMC Cancer. 2018. PMID: 29306329 Free PMC article.
-
Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.Oncotarget. 2017 Feb 14;8(7):11187-11198. doi: 10.18632/oncotarget.14492. Oncotarget. 2017. PMID: 28061437 Free PMC article.
-
Fumarate hydratase inactivation in renal tumors: HIF1α, NRF2, and "cryptic targets" of transcription factors.Chin J Cancer. 2012 Sep;31(9):413-20. doi: 10.5732/cjc.012.10102. Epub 2012 Jul 2. Chin J Cancer. 2012. PMID: 22776233 Free PMC article. Review.
-
Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1).Biochem Soc Trans. 2015 Aug;43(4):650-6. doi: 10.1042/BST20150041. Epub 2015 Aug 3. Biochem Soc Trans. 2015. PMID: 26551707 Review.
Cited by
-
KEAP1-mutant atypical meningioma: illustrative case.J Neurosurg Case Lessons. 2024 Sep 9;8(11):CASE24387. doi: 10.3171/CASE24387. Print 2024 Sep 9. J Neurosurg Case Lessons. 2024. PMID: 39250830 Free PMC article.
-
Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.Nat Commun. 2015 Mar 19;6:6336. doi: 10.1038/ncomms7336. Nat Commun. 2015. PMID: 25790038 Free PMC article.
-
Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1.Oncogenesis. 2019 Jan 15;8(2):7. doi: 10.1038/s41389-018-0116-9. Oncogenesis. 2019. PMID: 30647407 Free PMC article.
-
Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.Semin Cancer Biol. 2020 Apr;61:158-166. doi: 10.1016/j.semcancer.2019.10.016. Epub 2019 Nov 2. Semin Cancer Biol. 2020. PMID: 31689495 Free PMC article. Review.
-
Renal cell carcinoma: molecular biology and targeted therapy.Curr Opin Oncol. 2014 May;26(3):321-7. doi: 10.1097/CCO.0000000000000069. Curr Opin Oncol. 2014. PMID: 24675233 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous